Lookup NU author(s): Amy Heptinstall,
Dr Celine Cano,
Dr Ian Hardcastle
This is the authors' accepted manuscript of a review published in its final definitive form in 2018. For re-use rights please refer to the publishers terms and conditions.
Inhibition of cyclin-dependent kinases is an attractive approach to cancer therapy due to their vital role in cell growth and transcription. Pan-CDK inhibitors have shown some clinical benefit, and trials are ongoing. Selective CDK4 and CDK6 inhibitors have been licenced for the treatment of hormone responsive, RB positive breast cancer in combination with anti-hormonal agents. Selective inhibitors of CDKs 7, 8, 9 and 12 have been identified across a range of chemotypes.
Author(s): Heptinstall AB, Adiyasa IWS, Cano C, Hardcastle IR
Publication type: Review
Publication status: Published
Journal: Future Medicinal Chemistry
Print publication date: 01/06/2018
Online publication date: 30/05/2018
Acceptance date: 19/03/2018
ISSN (print): 1756-8919
ISSN (electronic): 1756-8927